Growth inhibitory effects of trastuzumab, erlotinib, and bevacizumab are proportional to average cellular levels of HER2 expression in breast cancer cell lines, and the effects of combinations of the three are additive in cell lines with high HER2 expression
Year: 2006
Type: article
Source: Cancer Research
Authors: David R. Emlet, Agnese A. Pollice, Charles A. Smith, Kathryn Brown, Deborah L. Kociban, Stanley E. Shackney
Institution: Allegheny-Singer Research Institute
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2737680693